Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Dec 29;3(12):2005-2007.
doi: 10.34067/KID.0005652022.

Optimizing Costimulation Blockade-Based Immunosuppression

Christoph Schwarz  1 , Moritz Muckenhuber  2 , Thomas Wekerle  2
Affiliations
Editorial

Optimizing Costimulation Blockade-Based Immunosuppression

Christoph Schwarz et al. Kidney360. .
No abstract available

Keywords: basic science; belatacept; immunosuppression therapy; kidney transplantation; nonhuman primate; transplantation.

PubMed Disclaimer

Conflict of interest statement

All authors have nothing to disclose.

Figures

Figure 1.
Figure 1.
After desensitization of highly sensitized rhesus macaques with carfilzomib in combination with belatacept (CTLA4Ig), a post-transplant belatacept-based maintenance therapy results in long-term control of the humoral response with a favorable effect on allograft survival. Created with BioRender.com.
See this image and copyright information in PMC

Comment on

References

    1. Wekerle T, Segev D, Lechler R, Oberbauer R: Strategies for long-term preservation of kidney graft function. Lancet 389: 2152–2162, 2017. 10.1016/S0140-6736(17)31283-7 - DOI - PubMed
    1. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, Gautreau C, Charron D, Glotz D, Suberbielle-Boissel C: Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 21: 1398–1406, 2010. 10.1681/ASN.2009101065 - DOI - PMC - PubMed
    1. Archdeacon P, Dixon C, Belen O, Albrecht R, Meyer J: Summary of the US FDA approval of belatacept. Am J Transplant 12: 554–562, 2012. 10.1111/j.1600-6143.2011.03976.x - DOI - PubMed
    1. Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, Moal MC, Mondragon-Ramirez GA, Kothari J, Polinsky MS, Meier-Kriesche HU, Munier S, Larsen CP: Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 374: 333–343, 2016. 10.1056/NEJMoa1506027 - DOI - PubMed
    1. Budde K, Prashar R, Haller H, Rial M, Kamar N, Agarwal A, De Fijter J, Rostaing L, Berger S, Djamali A, Leca N, Allamassey L, Gao S, Polinsky M, Vincenti F: Conversion from calcineurin inhibitor to belatacept-based maintenance immunosuppression in renal transplant recipients: A randomized phase 3b trial. J Am Soc Nephrol 32: 3252–3264, 2021. 10.1681/ASN.2021050628 - DOI - PMC - PubMed

MeSH terms

Substances